Category: News

BERGENBIO PROVIDES COVID-19 IMPACT ASSESSMENT

March 27, 2020

Bergen, Norway, 27 March 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2019

February 11, 2020

Bergen, Norway, 11 February 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS

January 15, 2020

First stage clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL…

Read More

BERGENBIO PRESENTS PRELIMINARY CLINICAL DATA FROM PHASE II COMBINATION TRIAL OF BEMCENTINIB AND LDAC IN ELDERLY AML PATIENTS AT ASH 2019

December 9, 2019

Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC)  in elderly AML patients…

Read More

BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER 2019

November 19, 2019

FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML)High Impact oral presentation of…

Read More

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

November 7, 2019

Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More